New funding will help Seaside Therapeutics, a Massachusetts-based company, develop biomarkers to track the success of treatments for autism, says Aileen Healy.
Expert opinions on trends and controversies in autism research.
Late this summer, a paper from Yale University researchers led by Jo Handelsman delivered some sobering news: There is still a clear bias against female scientists. The findings confirm the impression of many women in science, at all career levels, who feel undervalued.
We are on the verge of a seismic shift in the definition of autism spectrum disorders, says David Skuse. Under proposed guidelines for autism diagnosis, the canard that most people with the disorder cannot speak, or have such disordered language that they cannot sustain a conversation, has been abandoned.